Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK154 + ivonescimab
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AK154 + ivonescimab is an investigational combination therapy composed of AK154 and ivonescimab for the treatment of solid tumors, especially non-small cell lung cancer. Ivonescimab is a first-in-class, humanized, tetravalent bispecific monoclonal antibody that targets both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A), blocking PD-1–PD-L1-mediated immunosuppression and VEGF-A–VEGFR2-driven angiogenesis. Ivonescimab has demonstrated efficacy in combination with chemotherapy in clinical trials, improving progression-free survival and overall survival in advanced non-small cell lung cancer. The specifics of “AK154” as a separate component in this combination are not detailed in current literature, and it does not appear to correspond to a widely recognized or characterized independent agent. The developer for ivonescimab is Akeso Biopharma, with clinical collaborations involving Summit Therapeutics.
- Other names
- AK112AK-112AK 112SMT112SMT-112SMT 112EvoximabPD-1/VEGF bi-specific antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AK154 + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK154 + ivonescimab.